Autoimmune Autonomic Neuropathy

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Autoimmune autonomic neuropathy (AAN) typically presents as a subacute panautonomic neuropathy with orthostatic hypotension (OH), gastrointestinal dysmotility, sicca complex, and anhidrosis. The most convincing evidence of an autoimmune pathogenesis is the demonstration of ganglionic nicotinic acetylcholine receptor (AChR) antibodies in high titer in about 50% patients. The antibody level correlates with the severity of dysautonomia. This observation suggests that some cases of AAN result from an antibody-mediated impairment of synaptic transmission in autonomic ganglia. The diagnosis of idiopathic AAN requires the demonstration of autonomic failure of subacute or acute onset and the exclusion of a toxic or paraneoplastic cause. Treatment for AAN has largely been symptomatic. On the basis of the evidence of an autoimmune pathogenesis, it is reasonable to consider plasma exchange or intravenous (IV) immunoglobulin. Single case reports of a successful IV immunoglobulin therapy have all involved early therapeutic intervention. However, it is yet to be determined whether this treatment is effective for patients with a chronic progressive or chronic stable course.

Original languageEnglish (US)
Title of host publicationPrimer on the Autonomic Nervous System: Second Edition
PublisherElsevier Inc.
Pages324-327
Number of pages4
ISBN (Print)9780080473963, 9780125897624
DOIs
StatePublished - May 5 2004

Fingerprint

Intravenous Immunoglobulins
Antibodies
Hypohidrosis
Autonomic Ganglia
Primary Dysautonomias
Orthostatic Hypotension
Plasma Exchange
Passive Immunization
Poisons
Nicotinic Receptors
Synaptic Transmission
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

Vernino, S., Low, P. A., & Lennon, V. A. (2004). Autoimmune Autonomic Neuropathy. In Primer on the Autonomic Nervous System: Second Edition (pp. 324-327). Elsevier Inc.. https://doi.org/10.1016/B978-012589762-4/50088-8

Autoimmune Autonomic Neuropathy. / Vernino, Steven; Low, Phillip Anson; Lennon, Vanda A.

Primer on the Autonomic Nervous System: Second Edition. Elsevier Inc., 2004. p. 324-327.

Research output: Chapter in Book/Report/Conference proceedingChapter

Vernino, S, Low, PA & Lennon, VA 2004, Autoimmune Autonomic Neuropathy. in Primer on the Autonomic Nervous System: Second Edition. Elsevier Inc., pp. 324-327. https://doi.org/10.1016/B978-012589762-4/50088-8
Vernino S, Low PA, Lennon VA. Autoimmune Autonomic Neuropathy. In Primer on the Autonomic Nervous System: Second Edition. Elsevier Inc. 2004. p. 324-327 https://doi.org/10.1016/B978-012589762-4/50088-8
Vernino, Steven ; Low, Phillip Anson ; Lennon, Vanda A. / Autoimmune Autonomic Neuropathy. Primer on the Autonomic Nervous System: Second Edition. Elsevier Inc., 2004. pp. 324-327
@inbook{41f344d2a9be4ef2820d06c87ac0f8a6,
title = "Autoimmune Autonomic Neuropathy",
abstract = "Autoimmune autonomic neuropathy (AAN) typically presents as a subacute panautonomic neuropathy with orthostatic hypotension (OH), gastrointestinal dysmotility, sicca complex, and anhidrosis. The most convincing evidence of an autoimmune pathogenesis is the demonstration of ganglionic nicotinic acetylcholine receptor (AChR) antibodies in high titer in about 50{\%} patients. The antibody level correlates with the severity of dysautonomia. This observation suggests that some cases of AAN result from an antibody-mediated impairment of synaptic transmission in autonomic ganglia. The diagnosis of idiopathic AAN requires the demonstration of autonomic failure of subacute or acute onset and the exclusion of a toxic or paraneoplastic cause. Treatment for AAN has largely been symptomatic. On the basis of the evidence of an autoimmune pathogenesis, it is reasonable to consider plasma exchange or intravenous (IV) immunoglobulin. Single case reports of a successful IV immunoglobulin therapy have all involved early therapeutic intervention. However, it is yet to be determined whether this treatment is effective for patients with a chronic progressive or chronic stable course.",
author = "Steven Vernino and Low, {Phillip Anson} and Lennon, {Vanda A}",
year = "2004",
month = "5",
day = "5",
doi = "10.1016/B978-012589762-4/50088-8",
language = "English (US)",
isbn = "9780080473963",
pages = "324--327",
booktitle = "Primer on the Autonomic Nervous System: Second Edition",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Autoimmune Autonomic Neuropathy

AU - Vernino, Steven

AU - Low, Phillip Anson

AU - Lennon, Vanda A

PY - 2004/5/5

Y1 - 2004/5/5

N2 - Autoimmune autonomic neuropathy (AAN) typically presents as a subacute panautonomic neuropathy with orthostatic hypotension (OH), gastrointestinal dysmotility, sicca complex, and anhidrosis. The most convincing evidence of an autoimmune pathogenesis is the demonstration of ganglionic nicotinic acetylcholine receptor (AChR) antibodies in high titer in about 50% patients. The antibody level correlates with the severity of dysautonomia. This observation suggests that some cases of AAN result from an antibody-mediated impairment of synaptic transmission in autonomic ganglia. The diagnosis of idiopathic AAN requires the demonstration of autonomic failure of subacute or acute onset and the exclusion of a toxic or paraneoplastic cause. Treatment for AAN has largely been symptomatic. On the basis of the evidence of an autoimmune pathogenesis, it is reasonable to consider plasma exchange or intravenous (IV) immunoglobulin. Single case reports of a successful IV immunoglobulin therapy have all involved early therapeutic intervention. However, it is yet to be determined whether this treatment is effective for patients with a chronic progressive or chronic stable course.

AB - Autoimmune autonomic neuropathy (AAN) typically presents as a subacute panautonomic neuropathy with orthostatic hypotension (OH), gastrointestinal dysmotility, sicca complex, and anhidrosis. The most convincing evidence of an autoimmune pathogenesis is the demonstration of ganglionic nicotinic acetylcholine receptor (AChR) antibodies in high titer in about 50% patients. The antibody level correlates with the severity of dysautonomia. This observation suggests that some cases of AAN result from an antibody-mediated impairment of synaptic transmission in autonomic ganglia. The diagnosis of idiopathic AAN requires the demonstration of autonomic failure of subacute or acute onset and the exclusion of a toxic or paraneoplastic cause. Treatment for AAN has largely been symptomatic. On the basis of the evidence of an autoimmune pathogenesis, it is reasonable to consider plasma exchange or intravenous (IV) immunoglobulin. Single case reports of a successful IV immunoglobulin therapy have all involved early therapeutic intervention. However, it is yet to be determined whether this treatment is effective for patients with a chronic progressive or chronic stable course.

UR - http://www.scopus.com/inward/record.url?scp=84943422776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943422776&partnerID=8YFLogxK

U2 - 10.1016/B978-012589762-4/50088-8

DO - 10.1016/B978-012589762-4/50088-8

M3 - Chapter

SN - 9780080473963

SN - 9780125897624

SP - 324

EP - 327

BT - Primer on the Autonomic Nervous System: Second Edition

PB - Elsevier Inc.

ER -